Could a single gene therapy injection slow Alzheimer's?
NCT ID NCT05040217
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early study tests a gene therapy that delivers a protein called BDNF directly into the brain. The goal is to see if it is safe and can slow or prevent brain cell loss in people with early Alzheimer's or mild cognitive impairment. Only 12 participants will be enrolled in this first-in-human trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of California - San Diego
La Jolla, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Refresher training may extend brain benefits for veterans with mild memory issues